IDEXX Laboratories Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $464.36
- Today's High:
- $475.22
- Open Price:
- $465.79
- 52W Low:
- $317.06
- 52W High:
- $564.74
- Prev. Close:
- $471.51
- Volume:
- 369571
Company Statistics
- Market Cap.:
- $39.14 billion
- Book Value:
- 13.17
- Revenue TTM:
- $3.51 billion
- Operating Margin TTM:
- 29.82%
- Gross Profit TTM:
- $2.00 billion
- Profit Margin:
- 22.52%
- Return on Assets TTM:
- 23.91%
- Return on Equity TTM:
- 102.06%
Company Profile
IDEXX Laboratories Inc had its IPO on 1991-06-21 under the ticker symbol IDXX.
The company operates in the Healthcare sector and Diagnostics & Research industry. IDEXX Laboratories Inc has a staff strength of 11,000 employees.
Stock update
Shares of IDEXX Laboratories Inc opened at $465.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $464.36 - $475.22, and closed at $470.12.
This is a -0.29% slip from the previous day's closing price.
A total volume of 369,571 shares were traded at the close of the day’s session.
In the last one week, shares of IDEXX Laboratories Inc have slipped by -8.05%.
IDEXX Laboratories Inc's Key Ratios
IDEXX Laboratories Inc has a market cap of $39.14 billion, indicating a price to book ratio of 74.819 and a price to sales ratio of 10.3.
In the last 12-months IDEXX Laboratories Inc’s revenue was $3.51 billion with a gross profit of $2.00 billion and an EBITDA of $1.16 billion. The EBITDA ratio measures IDEXX Laboratories Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IDEXX Laboratories Inc’s operating margin was 29.82% while its return on assets stood at 23.91% with a return of equity of 102.06%.
In Q2, IDEXX Laboratories Inc’s quarterly earnings growth was a positive 71.2% while revenue growth was a positive 9.7%.
IDEXX Laboratories Inc’s PE and PEG Ratio
- Forward PE
- 50.2513
- Trailing PE
- 51.1399
- PEG
- 7.2076
Its diluted EPS in the last 12-months stands at $9.22 per share while it has a forward price to earnings multiple of 50.2513 and a PEG multiple of 7.2076. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IDEXX Laboratories Inc’s profitability.
IDEXX Laboratories Inc stock is trading at a EV to sales ratio of 11.0846 and a EV to EBITDA ratio of 37.6493. Its price to sales ratio in the trailing 12-months stood at 10.3.
IDEXX Laboratories Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.87 billion
- Total Liabilities
- $883.86 million
- Operating Cash Flow
- $-27470000.00
- Capital Expenditure
- $27.47 million
- Dividend Payout Ratio
- 0%
IDEXX Laboratories Inc ended 2024 with $2.87 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.87 billion while shareholder equity stood at $1.09 billion.
IDEXX Laboratories Inc ended 2024 with $5.57 million in deferred long-term liabilities, $883.86 million in other current liabilities, 10738000.00 in common stock, $4.04 billion in retained earnings and $364.21 million in goodwill. Its cash balance stood at $132.84 million and cash and short-term investments were $132.84 million. The company’s total short-term debt was $338,991,000 while long-term debt stood at $696.84 million.
IDEXX Laboratories Inc’s total current assets stands at $1.18 billion while long-term investments were $55.39 million and short-term investments were $0. Its net receivables were $461.86 million compared to accounts payable of $107.66 million and inventory worth $395.14 million.
In 2024, IDEXX Laboratories Inc's operating cash flow was $-27470000.00 while its capital expenditure stood at $27.47 million.
Comparatively, IDEXX Laboratories Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $470.12
- 52-Week High
- $564.74
- 52-Week Low
- $317.06
- Analyst Target Price
- $575.67
IDEXX Laboratories Inc stock is currently trading at $470.12 per share. It touched a 52-week high of $564.74 and a 52-week low of $564.74. Analysts tracking the stock have a 12-month average target price of $575.67.
Its 50-day moving average was $512.54 and 200-day moving average was $479.18 The short ratio stood at 4.59 indicating a short percent outstanding of 0%.
Around 92.2% of the company’s stock are held by insiders while 9132% are held by institutions.
Frequently Asked Questions About IDEXX Laboratories Inc
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.